<?xml version="1.0" encoding="UTF-8"?>
<ref id="B43-molecules-25-01015">
 <label>43.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Xie</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Vesuna</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Botlagunta</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Bol</surname>
    <given-names>G.M.</given-names>
   </name>
   <name>
    <surname>Irving</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Bergman</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Hosmane</surname>
    <given-names>R.S.</given-names>
   </name>
   <name>
    <surname>Kato</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Winnard</surname>
    <given-names>P.T.</given-names>
    <suffix>Jr.</suffix>
   </name>
   <name>
    <surname>Raman</surname>
    <given-names>V.</given-names>
   </name>
  </person-group>
  <article-title>NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3</article-title>
  <source>Oncotarget</source>
  <year>2015</year>
  <volume>6</volume>
  <fpage>29901</fpage>
  <lpage>29913</lpage>
  <pub-id pub-id-type="doi">10.18632/oncotarget.4898</pub-id>
  <?supplied-pmid 26337079?>
  <pub-id pub-id-type="pmid">26337079</pub-id>
 </element-citation>
</ref>
